Table 2.

Clinical and pathologic characteristics of the Asian population (n = 601)

CharacteristicsAdvanced prostate cancer
Age at diagnosis, y
 Median (IQR)73 (67–79)
 ≤73320 (53.2)
 >73281 (46.8)
Follow-up median (months)
 Mean (range)39 (3–125)
N (%)
Disease progression
 No ADT failure184 (30.7)
 ADT failure415 (69.3)
PCSM
 Alive499 (83.2)
 Dead of disease101 (16.8)
ACM
 Alive455 (75.8)
 Dead of any cause145 (24.2)
Clinical stage at diagnosis
 T1/T2189 (31.7)
 T3/T4/N1184 (30.8)
 M1224 (37.5)
Gleason score at diagnosis
 ≤6194 (33.0)
 7180 (30.6)
 ≥8214 (36.4)
PSA at ADT initiation (ng/mL)
 Median (IQR)35 (11–129)
 <34.6287 (49.6)
 ≥34.6292 (50.4)
PSA nadir (ng/mL)
 Median (IQR)0.18 (0.01–1.33)
 <0.2301 (50.8)
 ≥0.2292 (49.2)
Time to PSA nadir, months
 Median (IQR)10 (5–18)
 <10293 (49.4)
 ≥10300 (50.6)
Treatment modality
 ADT as primary treatment333 (55.7)
 ADT for postradical prostatectomy PSA failure68 (11.4)
 ADT for post RT PSA failure18 (3.0)
 Neoadjuvant/adjuvant ADT with RT125 (20.9)
 Others54 (9.0)

Abbreviation: IQR, interquartile range.